FindTrial
Sign In

Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent

DRUG6 trials

Sponsors

Academisch Ziekenhuis Leiden, Leids Universitair Medisch Centrum (LUMC), Centre Hospitalier Universitaire De Poitiers, Centre Hospitalier Universitaire De Saint Etienne, Nordsjaellands Hospital

Conditions

AspleniaChronic Obstructive Pulmonary Disease (COPD)HIV infectionHealthy adults receiving a profylactic vaccine to prevent pneumococcal infectionLymphomaPatient with medium or high risk for pneumococcal invasive infection

Phase 3

Using lymph nOde fine needle aspiration to assess the effeCt of pnEumococcal vAcciNe platform, Age and HIV infection on Germinal cEntre formation (OCEAN-AGE)
RecruitingCTIS2023-510354-16-00
Academisch Ziekenhuis LeidenHIV infection
Start: 2025-03-06Target: 75Updated: 2025-01-31

Phase 4

HEMATOVAC-Immunogenicity of an Anti-pneumococcal Combined Vaccination (PCV13+PPV23 versus PREVENAR20) in Lymphoma
RecruitingCTIS2024-517288-22-01
Centre Hospitalier Universitaire De PoitiersLymphoma
Start: 2021-01-29Target: 160Updated: 2025-10-23
Immunogenicity and safety of the 20-Valent pneumococcal conjugate vaccine (PCV-20) administered during an acute febrile illness in adults: a multicentre randomized non-inferiority trial: PREV-HOSPIT
RecruitingCTIS2024-517411-73-00
Centre Hospitalier Universitaire De Saint EtiennePatient with medium or high risk for pneumococcal invasive infection
Start: 2025-11-12Target: 1160Updated: 2025-07-16
Pneumococcal booster vaccine responsiveness to PCV20 in persons of 78-84 years of age
Active, not recruitingCTIS2025-521616-19-00
Rijksinstituut voor Volksgezondheid en Milieu (RIVM)Healthy adults receiving a profylactic vaccine to prevent pneumococcal infection
Start: 2025-08-11Target: 120Updated: 2025-08-07
(BIPAS) A prospective trial to assess Pneumococcal vaccine B cell response in patients without a spleen: a controlled study.
RecruitingCTIS2024-515363-63-00
Leids Universitair Medisch Centrum (LUMC)Asplenia
Start: 2025-11-07Target: 70Updated: 2025-08-11
COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients
Not yet recruitingCTIS2024-519163-18-00
Nordsjaellands HospitalChronic Obstructive Pulmonary Disease (COPD)
Target: 60Updated: 2025-12-08